

Ref. No: 1075
Date: 15/07/24
Subject: Biologic medicines in gastroenterology

REQUEST

Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Etrasimod
- Filgotinib
- Golimumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Mirikizumab
- Ozanimod
- Risankizumab
- Tofacitinib
- Upadacitinib
- Ustekinumab
- Vedolizumab

Q2. Could you please provide the numbers of patients treated for Crohn's Disease in the last 3 months with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilars
- Golimumab

- **Infliximab - Remicade**
- **Infliximab Biosimilars**
- **Risankizumab**
- **Upadacitinib**
- **Ustekinumab**
- **Vedolizumab**

RESPONSE

St Helens and Knowsley Teaching Hospitals NHS Trust and Southport and Ormskirk Hospital NHS Trust became a single legal entity known as Mersey and West Lancashire Teaching Hospitals NHS Trust on 1st July 2023, as such parts of the response may be provided in two sections relating to the hospital sites of each of the legacy organisations.

Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

Biologic Drugs	Gastroenterology STHK	Gastroenterology S&O
Adalimumab – Humira	<5	<5
Adalimumab Biosimilar	136	66
Etrasimod	0	0
Filgotinib	8	0
Golimumab	<5	<5
Infliximab – Remicade	<5	0
Infliximab Biosimilar	116	0
Mirikizumab	0	0
Ozanimod	<5	0
Risankizumab	<5	0
Tofacitinib	15	<5
Upadacitinib	6	7
Ustekinumab	106	39
Vedolizumab	28	45

Section 40: personal information

We are unable to provide precise figures when those figures refer to individuals in volumes of 5 or less due to the risk that individuals will be re-identified, as we are required to protect their identity under the General Data Protection Regulations & Data Protection Act 2018. In such circumstances Section 40(2) and Section 40(3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle which states that personal data should be processed “lawfully, fairly and in a transparent manner”. It is the lawful aspect of this principle which, in our view, would be breached by disclosure, and in such circumstances, Section 40 confers an absolute exemption on disclosure.

Q2. Could you please provide the numbers of patients treated for Crohn’s Disease in the last 3 months with the following biologic drugs:

- **Adalimumab - Humira**
- **Adalimumab Biosimilars**
- **Golimumab**
- **Infliximab - Remicade**
- **Infliximab Biosimilars**
- **Risankizumab**
- **Upadacitinib**
- **Ustekinumab**

St.Helens and Knowsley response

We do not have the data for indications.

Southport and Ormskirk response

Adalimumab - Humira	<5
Adalimumab Biosimilar	38
Golimumab	0
Infliximab - Remicade	0
Infliximab Biosimilar	37
Risankizumab	0
Upadacitinib	<5
Ustekinumab	33
Vedolizumab	20